JAB-3312

Phase 3Small molecule

JAB-3312 is one of 4 small molecule programs targeting Advanced Non-squamous Non-small-cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Non-Squamous Non-Small-Cell Lung CancerRecruiting

KRAS P.G12CRecruiting

Advanced Non-Squamous Non-Small-Cell Lung CancerPhase 3

Recruiting

KRAS P.G12CPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in KRAS P.G12C

#DrugCompanyPhaseTrials

JAB-3312

AAllist Pharmaceuticals, Inc.

Phase 3

1 2

Alimta

SShawn Eagle

Preclinical

1 3

JAB 21822

AAllist Pharmaceuticals, Inc.

Preclinical

1 4

JAB-21822

JJacobio Pharmaceuticals Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

KRAS P.G12C

NCT05288205

Q3 2030

Phase 3Recruiting

Advanced Non-Squamous Non-Small-Cell Lung Cancer

NCT06416410

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors3 trials

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Completed·AAllist Pharmaceuticals, Inc.·Phase 1/2·NCT04720976·58 enrolled

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

Completed·JJacobio Pharmaceuticals Co., Ltd.·Phase 1·NCT04045496·40 enrolled

A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China

Completed·AAllist Pharmaceuticals, Inc.·Phase 1·NCT04121286·17 enrolled

KRAS P.G12C1 trial

A Phase 1/2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Recruiting·AAllist Pharmaceuticals, Inc.·Preclinical·NCT05288205·240 enrolled

Advanced Non-squamous Non-small-cell Lung Cancer1 trial

An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Recruiting·AAllist Pharmaceuticals, Inc.·Phase 3·NCT06416410·392 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for JAB-3312. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JAB-3312 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JAB-3312. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Allist Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAllist Pharmaceuticals, Inc.

JAB-3312

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2030

Trials by Indication[1]

Patients With Advanced Solid Tumors3 trials

KRAS P.G12C1 trial

Advanced Non-squamous Non-small-cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News